参考文献 References
[1] 刘晓宁,张明发,沈雅琴.和厚朴酚治疗妇科肿瘤的药理作用及其机制的研究进展[J].现代药物与临床,2022,37(06):1420-1424.
[2] 汤梓莹,邓明港,宇传华,刘晴.中国卵巢癌疾病负担现状及趋势分析[J].国际妇产科学杂志,2022,49(02):222-227.
[3] Lheureux S，Gourley C，Vergote I，et al. Epithelial ovarian cancer[J]. Lancet，2019，393(10177)：1240-1253.
[4] 陈琳,杨红.上皮性卵巢癌类器官的基础和转化研究进展[J/OL].中国肿瘤:1-5[2022-06-28].http://kns.cnki.net/kcms/detail/11.2859.R.20220623.1139.002.html
[5] Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma[J]. Ann Oncol,2013,24(Suppl 10):x16-x21
[6] Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(suppl 10):x16-x21.
[7] Liu CL, Yuan RH, Mao TL. The Molecular Landscape Influencing Prognoses of Epithelial Ovarian Cancer. Biomolecules. 2021 Jul 7;11(7):998.
[8] Iida Y, Okamoto A, Hollis RL, et al. Clear Cell Carcinoma of the Ovary: A Clinical and Molecular Perspectiv [J]. Int J Gynecol Cancer 2021;31:605–616.
[9] Ku FC, Wu RC, Yang LY, et al. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study [J]. Formos Med Assoc. 2018;117(2):117-125.
[10] Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy[J]. Cancer. 2000;88(11):2584-2589.
[11] Okamoto A, Sehouli J, Yanaihara N, et al. Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma[J]. PLoS One. 2015;10(2):e0116977. doi:10.1371/journal.pone.0116977
[12] Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective[J]. Int J Gynecol Cancer. 2021;31(4):605-616.
[13] Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma[J]. Cancer Sci. 2008;99(4):653-658.
[14] 靳成文,苏荣家.卵巢透明细胞癌研究进展[J].现代妇产科展,2020,29(12):947-949+952.
[15] Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers[J]. Gynecol Oncol. 2008;109(3):370-376.
[16] Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective[J]. Int J Gynecol Cancer. 2021;31(4):605-616.
[17] Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary[J]. Am J Obstet Gynecol. 2011;205(5):480.
[18] Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16[J]. J Biol Chem. 2001;276(29):27371-27375.
[19] Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review[J]. Clin Pathol. 2013;66(4):273-281.
[20] 林燕玲,王瑛,黄颀,康灵,邢维珍,刘伟,黎先萍.血清miR-552-5p、HE4及CA125在上皮性卵巢癌中的表达及其临床价值[J].现代肿瘤医学,2022,30(13):2410-2414.
[21] Charkhchi P, Cybulski C, Gronwald J, et al. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 2020;12(12):3730.
[22] Ma C. Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis[J]. World J Surg Oncol. 2022;20(1):154.
[23] Rossi L, Verrico M, Zaccarelli E, et al. Bevacizumab in ovarian cancer: A critical review of phase III studies[J]. Oncotarget. 2017;8(7):12389-12405.
[24] Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol. 2017;18(6):779-791.
[25] 杜钢军,时小燕.治疗癌症的新途径:靶向肿瘤微环境[J].国际药学研究杂志,2011,38(05):336-340.
[26] 殷爱军,李鹏,宋坤,姜洁,孔北华.安罗替尼在妇科肿瘤治疗中的现状及研究进展[J].现代妇产科进展,2022,31(05):384-388+393.
[27] 张琪琳,丁玉峰,戴冰,舒亚民.培美曲塞联合贝伐珠单抗维持治疗晚期非鳞状非小细胞肺癌成本-效果分析[J].中国药业,2022,31(10):106-111.
[28] 慈明伟,刘楠,高璐璐.奥希替尼+培美曲塞及贝伐单抗三联化疗对EGFR突变型NSCLC的疗效分析[J].国际医药卫生导报,2022,28(10):1418-1421.
[29] 王月,李蕾蕾,朱琳琳.贝伐珠单抗联合化疗治疗转移性结直肠癌对患者血清VEGF和TAP水平的影响[J].临床和实验医学杂志,2022,21(09):959-963.
[30] 益东晋.抗生素对贝伐珠单抗治疗转移性结直肠癌疗效的影响[J].中外医疗,2022,41(14):95-98+120.DOI:10.16662/j.cnki.1674-0742.2022.14.095.
[31] 张轶群,琚长斌,李芳,刘睿,程玉峰.非小细胞肺癌患者贝伐珠单抗相关不良反应临床分析[J].药物不良反应杂志,2022,24(05):233-238.
[32] Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. Hematol Oncol 11, 120 (2018). doi.org/10.1186/s13045-018-0664-7
[33] Sun L, Liu C, Li Y. Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma. Comput Math Methods Med. 2022;2022:4600145. Published 2022 Jun 10. doi:10.1155/2022/4600145
[34] Silk Ann W,Saraiya Biren,Groisberg Roman et al. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.[J] .Eur J Med Res, 2022, 27: 107.
[35] Kennedy Fiona,Shearsmith Leanne,Holmes Marie et al. Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study.[J] .BMC Cancer, 2022, 22: 726.
[36] Nanthamongkolkul Kulisara,Wattanapaisal Panote,Boonyapipat Sathana et al. Appendiceal tumors in patients undergoing primary surgery for mucinous ovarian tumors in a tertiary hospital, in Southern Thailand.[J] .Taiwan J Obstet Gynecol, 2022, 61: 657-662.
[37] Lee Wen-Ling,Yang Szu-Ting,Wang Peng-Hui,Dehydroepiandrosterone (DHEA) adjuvant and poor ovarian responders.[J] .Taiwan J Obstet Gynecol, 2022, 61: 571-572.
[38] Bernard Juliette,Mehros Wala,Gregoire Jean et al. Low BRCA1/2 germline mutation rate in a French-Canadian population with a diagnosis of epithelial tubo-ovarian carcinoma.[J] .J Obstet Gynaecol Can, 2022, undefined: undefined.
[39] Motallebi Mahzad,Bhia Mohammed,Rajani Huda Fatima et al. Naringenin: A potential flavonoid phytochemical for cancer therapy.[J] .Life Sci, 2022, undefined: 120752.
[40] Fotopoulou Christina,Khan Tabassum,Bracinik Juraj et al. Outcomes of gynecological cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-GO Cancer study.[J] .Am J Obstet Gynecol, 2022, undefined: undefined.
[41] Zamani Fatemeh,Abdolrazaghnejad Aghdas,Ameli Fereshteh et al. Struma ovarii: A case report and review the literature.[J] .Int J Surg Case Rep, 2022, 96: 107318.